Dylan Livingston, Founder Alliance For Longevity Initiatives on Longevity Policy, Right to Try, and Scaling the Longevity Dividend

Dylan Livingston on Longevity Policy, Right to Try, and Scaling the Longevity Dividend Jason Wright interviews Dylan Livingston, founder of the Alliance for Longevity Initiatives (A4LI), about advancing longevity through policy rather than products. Livingston traces his interest from discovering Aubrey de Grey as a teen to COVID-era experiences with his grandfather, which renewed his focus and led him to launch A4LI in 2022 as a coalition of longevity biotech companies. He describes passing a California resolution prioritizing longevity and healthy aging, framing the goal as achieving a “longevity dividend” worth trillions through reduced healthcare costs and increased productivity, and argues therapeutics can democratize longevity more than intensive lifestyle protocols. They discuss Right to Try, its limits under terminal-only access and liability concerns, and A4LI’s work expanding access in Montana and New Hampshire for Phase 1-safe therapies. Livingston highlights AI-driven acceleration in biotech, cellular reprogramming with Yamanaka factors, and previews A4LI’s Georgetown DC summit featuring major companies, researchers, policymakers, and a Capitol Hill briefing on US-China biotech competition. 00:00 Cold Open Banter 01:05 Why Longevity Policy 02:17 Dylan Origin Story 05:39 Launching The Alliance 08:24 Sponsor Message 09:18 California Policy Playbook 10:49 Longevity Dividend Explained 12:39 Therapeutics As Equalizer 13:44 Moral Case For Healthspan 17:48 Right To Try Primer 21:17 Fixing Right To Try 22:23 Biotech Valley Of Death 25:22 AI And Medical Gatekeeping 26:01 AI Health Coach Teaser 26:35 Plan Aware Health Coaching 27:31 Longevity Goals And Motivation 29:38 AI Accelerating Biotech 32:10 Cell Reprogramming Breakthroughs 34:32 Aging As Root Cause Policy 37:10 Wellness Mindset And Agency 40:15 Prevention Limits And Lifelong Care 44:33 DC Summit Agenda Preview 46:24 Hill Briefing And Biotech Race 49:20 Wrap Up And Medical Disclaimer